Current stock page

Financial Data

STOK Financial Data

Revenue · Earnings · Margins · Balance Sheet · Cash Flow

HealthcareBiotechnologyScore data as of Nov 13, 2026

STOKStoke Therapeutics, Inc.

Healthcare / Biotechnology

Low Priority

Relative Laggard

BearishEdge 2/10
$26.68+$0.48 (+1.83%)

Latest quote

  • Momentum
    47
  • Value
    22
  • Quality
    42
  • Risk resilience
    59
  • Sentiment
    —
algovestiq.comScore data as of Nov 13, 2026

Financial Data Overview

Detailed revenue, earnings, margins, balance sheet, cash flow, valuation metrics, technical indicators, and risk measures for deeper research.

Quarterly periods
8
Fundamental metrics
10
Technical indicators
12
Risk measures
6

Quarterly Financial Statements

Updated Nov 16, 2026.

Income statement
8 periods
Metric2026-09-302026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-31
Revenue$11.26M$9.33M$6.23M$1.4M$10.63M$13.82M$158.57M$22.61M
Gross Profit$11.26M$8.19M$5.18M$347K$9.64M$13.82M$158.57M$22.61M
Operating Income-$77.32M-$65.43M-$53.42M-$61.44M-$43.09M-$27.3M$111.24M-$13.65M
Net Income-$73.64M-$61.62M-$50M-$57.93M-$38.35M-$23.48M$112.88M-$10.48M
EPS-$1.08-$0.93-$0.79-$0.99-$0.65-$0.4$1.95-$0.18
Cash flow statement
8 periods
Metric2026-09-302026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-31
Operating Cash Flow-$62.69M-$56.59M-$60.58M-$30.45M-$30.37M-$25.42M$131.83M-$23.19M
Capital Expenditure-$2.85M-$1.98M-$353K-$232K-$132K-$154K-$152K-$42K
Free Cash Flow-$65.54M-$58.56M-$60.94M-$30.69M-$30.5M-$25.58M$131.68M-$23.24M
Net Cash Provided By Operating Activities-$62.69M-$56.59M-$60.58M-$30.45M-$30.37M-$25.42M$131.83M-$23.19M
Balance sheet
8 periods
Metric2026-09-302026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-31
Total Assets$406.69M$393.97M$443.28M$418.43M$360.26M$384.51M$406.89M$271.56M
Total Debt$0$2.68M$3.42M$3.01M$2.91M$2.3M$2.35M$4.77M
Cash And Cash Equivalents$107.27M$110M$155.66M$84.22M$83.39M$101.47M$274.82M$127.98M
Total Liabilities$54.1M$48.42M$48.4M$65.98M$52.16M$49.57M$56.81M$42.53M
Total Stockholders Equity$352.59M$345.55M$394.88M$352.46M$308.11M$334.94M$350.07M$229.02M
Key financial metrics
8 periods
Metric2026-09-302026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-31
P/E ratio————36.6115.0410.55—
P/B ratio5.055.655.245.634.822.361.522.21
P/S ratio64.65———————
Debt To Equity00.010.010.010.010.010.010.02
Free Cash Flow Yield-12.10%-9.26%-7.14%2.27%3.53%7.74%13.05%-17.21%
Financial ratios
8 periods
Metric2026-09-302026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-31
P/E ratio————36.6115.0410.55—
P/B ratio5.055.655.245.634.822.361.522.21
P/S ratio64.65———————
Return On Equity-68.98%-60.17%-42.99%-1.95%13.17%15.67%14.36%-38.85%
Debt To Equity00.010.010.010.010.010.010.02

Current Stock Metrics

Current fundamental, technical, and risk readings in one place.

Fundamental metrics
MetricValue
Pe-7.04x
Pb5.17x
Revenue Growth Yoy5.86%
EPS Growth Yoy-66.15%
Gross Margin88.52%
Operating Margin-913.12%
ROE-67.30%
ROIC-72.01%
Debt To Equity0
FCF Yield-12.36%

As of Nov 13, 2026

Technical indicators
MetricValue
Close$26.68
Volume420,232
RSI (14)51.32
MACD0.24
MACD signal0.13
MACD histogram0.11
ADX (14)17.32
SMA (50)$26.45
SMA (200)$30.79
ATR (14)$1.28
Historical volatility (annualized)48.94%
Volume (20-day average)1.36M

As of Nov 13, 2026

Risk measures
MetricValue
Resilience score59/100
Beta0.96
Annual volatility53.19%
Max Drawdown-41.33%
Sharpe Ratio0.23
VaR (95%, 1-day)-5.03%

As of Nov 13, 2026

Detailed Metrics

Additional measures remain available here while the decision pages stay focused.

Additional fundamental metrics

No additional fundamental metrics are available.

Additional technical indicators

No additional technical indicators are available.

Additional risk measures

No additional risk measures are available.

STOK Financial Data FAQ

What is Stoke Therapeutics, Inc.'s revenue?

Stoke Therapeutics, Inc.'s revenue is one of the core financial data points for STOK. Use it with revenue growth, margins, and EPS to understand whether sales are translating into earnings power.

Is Stoke Therapeutics, Inc.'s revenue growing?

Revenue growth shows whether Stoke Therapeutics, Inc. is expanding from prior periods. Compare growth with margins and free cash flow because faster sales growth is more valuable when profitability holds up.

What is STOK's EPS?

STOK's EPS, or earnings per share, helps connect net income to each share. EPS should be compared with EPS growth, P/E ratio, and analyst expectations.

What is Stoke Therapeutics, Inc.'s net income?

Stoke Therapeutics, Inc.'s net income shows profit after costs, taxes, and other expenses. It should be read with revenue, operating margin, EPS, and free cash flow.

How much free cash flow does Stoke Therapeutics, Inc. generate?

Free cash flow shows how much cash Stoke Therapeutics, Inc. generates after capital spending. It is useful for judging reinvestment capacity, buybacks, debt reduction, and valuation support.

How much cash and debt does Stoke Therapeutics, Inc. have?

Cash and debt help frame STOK's balance-sheet flexibility. Compare liquidity and leverage with free cash flow and profitability before judging financial strength.